Lirilumab
Based on 3 publication(s) in Google Scholar
Lirilumab (IPH2102) is an anti-KIR monoclonal antibody, and shows antitumor activity. Lirilumab can be used in Leukemia, squamous cell carcinoma of the head and neck (SCCHN) research.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 96.80%
- CAS 番号: 1000676-41-4
- 分子量:145.52 kDa
-
保管条件:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
MedChemExpress（MCE）の使用を引用している文献 Lirilumab
More
生物活性
Human IgG4 kappa
Human
KIR
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Rag1KO-Tg KIR mice injected with tumor cells[2]
-
Dosage:15 mg/kg
-
Administration:intravenous injection; 15 mg/kg; once
-
Result:Showed 6 of 7 mice survival over a 100-day period, whereas untreated or IC-treated mice all died.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG4 kappa
ELISA, FACS, Functional assay
-
Immobilized KIR2DL1 Protein, Human (HEK293, His) can bind Lirilumab. The EC50 for this effect is 16.59 ng/mL.
化学情報
-
CAS 番号 1000676-41-4
-
性状 Liquid
-
分子量 145.52 kDa
-
Color Colorless to light yellow
-
SMILES
[Lirilumab]
-
別名
IPH2102
-
輸送条件
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
保管条件
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (3)
-
Journal Impact Factor
-
Most Recent
-
Nat Commun
MHC-I upregulation safeguards neoplastic T cells in the skin against NK cell-mediated eradication in mycosis fungoides. [Abstract]2024 Jan 25;15(1):752. PMID: 38272918 -
Cell Death Dis
Targeting RNA polymerase I to boost natural killer cell anticancer activity in multiple myeloma. [Abstract]2025 Nov 28;16(1):865. PMID: 41315184 -
J Immunother Cancer
2024 Jul 1; 12(7): e009410. PMID: 38955423
純度とドキュメンテーション
-
データシート (260 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
参考文献
[1]. Hanna GJ, et al. Neoadjuvant and Adjuvant Nivolumab and Lirilumab in Patients with Recurrent, Resectable Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2022 Feb 1;28(3):468-478. [Content Brief]
[2]. Kohrt HE, et al. Anti-KIR antibody enhancement of anti-lymphoma activity of natural killer cells as monotherapy and in combination with anti-CD20 antibodies. Blood. 2014 Jan 30;123(5):678-86. [Content Brief]
Calculators
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Lirilumab 関連分類
HY-P99208 関連分類
Powered by Bioz